Indrop-d

Quick links to important sections

Indrop-d

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Indrop-d

Quick Facts

Property Description
Active ingredient Colecalciferol (Vitamin D3)
Form Oral liquid (drops/solution), Capsule, Tablet
Pharmacological class Vitamin D Analog / Prohormone
Common use Supporting bone health and mineral balance
Origin Endogenous (skin synthesis) or Exogenous (supplementation)

What is Indrop-d: Identity and Active Ingredient

Indrop-d is a pharmaceutical preparation whose sole active ingredient is Colecalciferol, which is chemically identical to Vitamin D3. This compound is a single-ingredient product derived from a precursor that is either synthesized endogenously in the skin upon sun exposure or introduced exogenously through diet.

Colecalciferol is categorized as a secosteroid and a prohormone, meaning the compound itself is largely inactive. Its therapeutic purpose relies on the body's conversion of Colecalciferol into the potent hormone form, Calcitriol, which then carries out the primary regulatory work. As a prohormone, Colecalciferol serves as the foundational material for the active regulatory hormone in the body.


Pharmacological Class and Essential Function

Indrop-d belongs to the pharmacological class of Vitamin D Analogs, and its core function is to maintain calcium and phosphate homeostasis. It acts as a critical regulator of the mineral economy by significantly enhancing the absorption of calcium from the gastrointestinal tract and regulating its subsequent levels in the bloodstream. This essential action is clinically recognized for its support of skeletal structure.

By governing calcium and phosphate availability, the drug provides the fundamental support necessary for bone mineralization and overall skeletal integrity. The compound is vital for maintaining the necessary balance of minerals for strong bones. A typical neutral use scenario involves supplementing individuals with limited sun exposure or specific dietary restrictions to support their mineral balance.


Available Forms and Physical Composition

Colecalciferol is characterized as a fat-soluble compound, a property that governs its formulation. Therefore, Indrop-d is commonly offered in forms such as oral liquid solutions (drops), soft gelatin capsules, or various tablet forms for oral administration. Indrop-d's formulation often targets infants and children via its liquid drop form, making it easier to administer to younger patient groups.

Due to its solubility profile, the liquid and capsule preparations typically contain an oily vehicle, such as medium-chain triglycerides, to ensure stability and proper absorption from the small intestine. This lipid-based structure is a necessary characteristic for formulating this type of medication to facilitate adequate fat absorption when taking this product.

Regulatory References

  1. MedlinePlus, Vitamin D Reference

What side effects are possible with Indrop-d?

Possible Side Effects and Safety Information

The safety profile of Indrop-d (Colecalciferol) is structured primarily around its effect on mineral regulation, as documented in official prescribing information.

Frequency-Classified Adverse Reactions

Adverse reactions are classified by frequency based on regulatory standards. The most relevant effects are related to the accumulation of minerals in the body:

  • Uncommon (affecting less than 1 in 100 people): Hypercalcaemia (excessive calcium in the blood) and Hypercalciuria (excessive calcium in the urine).
  • Rare (affecting less than 1 in 1,000 people): Effects are generally reported in the Gastrointestinal system (e.g., nausea, abdominal pain, constipation, flatulence) and the Skin and subcutaneous tissue (e.g., pruritus, rash, urticaria).

Serious Adverse Reactions and Restrictions

Prolonged use at high levels may lead to serious adverse reactions, collectively known as Hypervitaminosis D. This condition is documented to potentially cause irreversible renal impairment and nephrocalcinosis (calcification of the kidneys). Persistent Hypercalcaemia is also associated with a risk of cardiac arrhythmia.

Official labeling defines situations where the medicine should not be used. It is Contraindicated in individuals with pre-existing conditions such as Hypercalcaemia, Hypercalciuria, or Nephrolithiasis (kidney stones). Caution is specifically advised for patients with Sarcoidosis or Severe Renal Insufficiency.

For patients on long-term treatment, the official regulatory documents advise that monitoring of serum and urinary calcium levels, along with kidney function, is necessary.

Overdose and Emergency Response

Overdose and when to seek help

Overdose of Colecalciferol (Indrop-d) is characterized by hypervitaminosis D, leading to sustained high levels of calcium in the blood, known as hypercalcemia. All documented manifestations and severe outcomes arise from this mineral imbalance.

Feature Official Regulatory Statement
Documented Manifestations: Symptoms may include nausea, vomiting, metallic taste, constipation, polyuria, polydipsia, headache, weakness, and fatigue.
Severe Outcomes: Severe overdose may lead to life-threatening complications such as cardiac arrhythmias, hypertension, and permanent renal damage, including nephrocalcinosis and renal failure.
Emergency Action: Immediate medical attention must be sought for any suspected overdose or the onset of severe symptoms. The product must be immediately discontinued.
Management Note: No specific antidote is known. Treatment is symptomatic and supportive, requiring continuous monitoring of serum calcium levels and kidney function.

Infants and small children are noted in regulatory information as being particularly sensitive to Colecalciferol toxicity. The required action for severe cases involves aggressive rehydration and the use of officially described supportive measures, such as calcium-lowering agents, to reverse the effects of hypercalcemia. The regulatory guidance highlights that specialized professional monitoring is necessary until all documented manifestations of toxicity have resolved.

Therapeutic Uses of Indrop-d

What Indrop-d Treats: Main Uses and Benefits

Indrop-d (Colecalciferol) is commonly used to help manage conditions presenting with systemic or localized discomfort related to vitamin D deficiency. It supports the body's ability to maintain mineral balance for stability. The medicine is applied across domains where additional symptomatic support is needed.

The therapeutic use is relevant for skeletal integrity and bone health, relief of chronic musculoskeletal discomfort, and management of mineral imbalance. It is applied in the management of conditions, including rickets in children, osteomalacia in adults, and hypocalcemia.

Supportive mineral therapy is considered relevant for easing the functional strain on the skeletal structure and assists with maintaining functional stability during periods of heightened symptoms.

This medication is relevant for easing the symptomatic burden of chronic, generalized bone pain and proximal muscle weakness. For older adults, this support may assist with maintaining muscle strength and is considered relevant for easing the risk of falls. It also helps address symptom clusters like painful muscle cramps or spasms and sensory tingling. It is commonly used when short-term symptomatic assistance is needed for patient groups, including infants and those with limited sun exposure.

Quick Fact: Relief for Musculoskeletal Symptoms
Indrop-d is applied to help manage symptoms related to physical discomfort like chronic bone pain and muscle aches that interfere with daily functioning.

Regulatory References

  1. NIH MedlinePlus overview on Cholecalciferol

Eligibility and Restrictions for Use

Who can and cannot use Indrop-d?

Eligibility to use Indrop-d (Colecalciferol) is strictly defined by regulatory bodies and centers primarily on a patient's pre-existing calcium status and kidney function.

Eligibility Status Populations and Conditions
Allowed Use Adults and the Elderly. Adolescents are generally eligible from 12 years of age for many standard formulations.
Use Contraindicated Must not be used by patients with Hypersensitivity to the drug or excipients, Hypercalcaemia (high blood calcium), Hypercalciuria, Hypervitaminosis D, Nephrolithiasis (kidney stones), or Severe renal impairment.

Age and Comorbidity Limitations

The medicine is not recommended for children under 12 years for certain capsule or tablet strengths. Use is constrained in patients with Pseudohypoparathyroidism, where alternative vitamin D derivatives are advised. High doses must be avoided during pregnancy due to the risk of fetal harm; lower doses are permitted for confirmed deficiency. During lactation, use is generally allowed, but the dose passing to the infant must be considered. Caution is mandatory for patients with non-severe renal impairment and sarcoidosis, as both require regular calcium monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Indrop-d (Colecalciferol) interacts with specific medicinal products and substances through mechanisms that alter its absorption, breakdown, or mineral-regulating effect. These documented interaction patterns are classified based on official regulatory information.


Documented Interaction Patterns

Interaction Type Interacting Medicines and Substances
Reduced Systemic Exposure (Impaired Absorption) Bile Acid Sequestrants (e.g., Cholestyramine, Colestipol) and Mineral Oil laxatives are documented to impair the absorption of Colecalciferol in the gastrointestinal tract, leading to reduced concentrations in the body.
Reduced Plasma Concentration (Increased Catabolism) Certain Anticonvulsants (e.g., Phenytoin, Carbamazepine) and Antifungal Medicines are documented to increase the metabolic breakdown (catabolism) of Colecalciferol.
Risk of Hypercalcaemia (Additive Effect) Thiazide Diuretics (e.g., Bendroflumethiazide) reduce the excretion of calcium, creating a documented risk of excessive blood calcium levels when co-administered with Colecalciferol.

Specific Interaction Constraints

The co-administration of Indrop-d with other high-dose Vitamin D or calcium products is officially documented to carry a risk of excessive calcium levels. Regulatory sources also note that consumption of Grapefruit Juice may alter the medicine's blood concentrations and effects. The interaction profile necessitates attention to agents that officially decrease drug exposure and those that increase the documented risk of mineral imbalance.

Mechanism of Action

The mechanism of Colecalciferol (Vitamin D3) is defined by its role as an inactive prohormone, requiring enzymatic conversion primarily by the kidneys into the active hormonal agonist, Calcitriol. Calcitriol binds to and activates the intracellular Vitamin D Receptor (VDR), initiating genomic regulation within target cells. This VDR activation is the fundamental step that alters the expression of proteins involved in mineral transport.

This action is crucial for controlling key aspects of mineral homeostasis by increasing the transepithelial transport of calcium and phosphate from the small intestine and promoting mineral conservation by the kidneys. Furthermore, the active hormone exerts a direct negative feedback effect on the parathyroid glands, suppressing the synthesis of Parathyroid Hormone (PTH). By regulating systemic availability of these minerals, the mechanism assists in creating the physiological environment for the regulated deposition of minerals onto the bone matrix.

Dosage and Administration Information

Administration Scope and Regimens

Indrop-d, whose active ingredient is Colecalciferol, is approved for oral administration only, available across various forms including liquid drops, capsules, and tablets. The use protocol is generally divided into two distinct phases: an initial correction phase and a long-term maintenance phase. The initial phase often utilizes higher doses, such as 50,000 IU once weekly, to establish adequate levels, followed by a switch to a lower daily regimen for sustained support. Typical daily maintenance doses range from 1000 IU to 2000 IU.

Administration Conditions and Handling

As a fat-soluble compound, official instructions dictate that Indrop-d must be taken with the main meal of the day or a high-fat meal to maximize proper absorption. Non-chewable capsules and tablets must be swallowed whole, while the oral liquid drops can be mixed with food or beverage for easier intake.

For administration across different age groups, specific daily dose guidelines apply; for example, lower doses (e.g., 400 IU) are specified for infants. Furthermore, use requires the monitoring of serum levels of 25(OH)D to determine necessary dose adjustments and guide the transition from initial to maintenance therapy. If a scheduled dose is missed, regulatory guidance instructs that the next scheduled dose must not be doubled to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Indrop-d


Evidence for Use in Correcting Nutritional Deficiency

Research has studied Indrop-d (Colecalciferol) in populations where nutritional vitamin D deficiency is present, a state associated with conditions such as rickets in children and osteomalacia in adults. Studies monitored critical blood biomarkers, including serum levels of 25( OH) D, calcium, and phosphate. Findings consistently describe patterns of change toward expected ranges in the observed populations. Radiographic studies reported on the evolution of bone lesions and associated structural changes. Studies note that outcomes were often associated with concurrent adequate calcium intake. Evidence is limited when patients have underlying conditions that might interfere with absorption, such as severe malabsorption syndromes.


Evidence for Use in Skeletal Integrity and Fall Risk

Research has examined Indrop-d in contexts related to skeletal integrity and fall-related outcomes, particularly in older adults. This area relies on large-scale Randomized Controlled Trials (RCTs) monitoring incidence of non-vertebral fractures, hip fractures, and the rate of falls. Some systematic reviews reported mixed findings regarding these outcomes. Data show patterns related to the observation that any changes were often associated with studies where Indrop-d was evaluated in combination with calcium.


Evidence in Special Study Populations

Research has explored Indrop-d's effects across various patient groups. The primary populations evaluated include infants and children for rickets and older adults for skeletal health. Within these groups, studies monitored individuals with low baseline vitamin D levels versus those with sufficient levels. Findings describe patterns observed in these studied groups, but results apply only to the populations investigated. Data for certain groups, such as those with specific comorbidities or pregnant populations, remain limited in the overall high-level evidence landscape.


What is Still Uncertain in the Research Landscape

The primary area where evidence is still being contextualized is the exact observation and consistent patterns of Indrop-d monotherapy (without calcium) in the general context of fracture and fall prevention in adults who are not severely deficient. Findings were mixed or inconsistent in many large trials focused on these outcomes. Research indicates that evidence quality varies across studies, and comparative evidence regarding different dosages or administration frequencies is sometimes lacking. These research limitations mean that data for certain groups and the long-term, generalized outcomes are still being evaluated.

Frequently Asked Questions (FAQ)

Common questions about Indrop-d (FAQ)


Q: What is the main reason Indrop-d is prescribed?

The primary therapeutic purpose of Indrop-d, whose active ingredient is Colecalciferol, is to regulate the body's calcium and phosphate homeostasis (balance). Official documentation states it is prescribed for specific indications, such as treating documented Vitamin D deficiency or insufficiency, to support bone health and overall mineral balance.


Q: How quickly can I expect to notice any effects from Indrop-d?

According to the official product information, there is a time lag of 10 to 24 hours between the administration of the drug and the initiation of its effects. This time lag is related to the required metabolic steps the compound must undergo in the body to become fully active.


Q: Can Indrop-d be used in children?

Official documents describe that use in children is generally allowed, but dosing is typically determined by a healthcare provider based on the child's age and weight. It is noted that certain strengths of the capsules or tablets may not be recommended for children under 12 years of age.


Q: Does Indrop-d interact with commonly used over-the-counter pain relievers?

Regulatory documents listing known interactions do not typically highlight common over-the-counter pain relievers as specific agents that alter Colecalciferol’s absorption or metabolism. Official interaction profiles generally focus on medications known to affect the absorption or metabolism of the drug, or those that could significantly affect resulting calcium levels.


Q: What happens if I stop taking Indrop-d suddenly?

Because the drug is fat-soluble and stored in the body, its effects can persist for two or more months even after treatment has stopped. This slow elimination is a characteristic of the drug's properties as a stored compound.


Q: Does Indrop-d cause weight gain or weight loss?

While weight gain is not a commonly listed side effect, weight loss (anorexia) is documented as an early sign of Hypervitaminosis D (Vitamin D overdose). This adverse reaction is linked to excessive levels of the compound in the body.


Q: What foods or supplements should be avoided when taking Indrop-d?

Official documents state that consuming large quantities of grapefruit or grapefruit juice may alter the drug's blood concentrations. Additionally, combining the drug with other high-dose Vitamin D or calcium supplements carries a documented risk of excessive calcium levels in the blood.


Q: Can Indrop-d be taken by people with kidney or liver issues?

Official guidelines state that use is contraindicated (not recommended) for patients with severe renal impairment. Regulatory texts also advise that compromised hepatic function (liver issues) may alter the drug's metabolic pathway, and an alternative form of Vitamin D may need to be considered.


Q: What are the reported effects of Indrop-d on mood or energy?

Official safety summaries indicate that rare adverse events associated with the drug may include effects on the central nervous system. These documented effects can include mood or mental changes, confusion, or a feeling of weakness or lack of strength (asthenia).


Q: Can Indrop-d cause issues with blood pressure?

High levels of calcium in the blood (Hypercalcaemia), a potential adverse effect of the drug, are noted to carry an associated risk of cardiac arrhythmia. Some general adverse event lists may also include effects like dizziness.


Q: Does Indrop-d interact with birth control pills?

Official interaction documents detailing known drug interactions do not typically list hormonal contraceptives (birth control pills) as specific agents that alter the absorption or metabolism of Colecalciferol. The focus of regulatory interaction profiles is on medications known to significantly interfere with the drug's efficacy or safety.


Q: How does Indrop-d affect the immune system?

Official medical overviews note that the active form of the drug has been researched for its potential roles in the body that include the modulation of immune function and support for inflammatory balance. The primary documented purpose, however, remains calcium and phosphate homeostasis.


Q: Is Indrop-d known to cause hair loss?

Hair loss (alopecia) has been reported as an adverse reaction in some safety summaries documented by regulatory bodies. It is listed as a potential effect, although the frequency is generally described as rare or unknown in official classifications.


Q: What are the possible interactions between Indrop-d and herbal supplements?

Official documents list interactions with specific pharmaceutical agents and substances like grapefruit juice. The safety profile for the broad category of herbal supplements is generally not documented, but supplements containing high-dose Vitamin D or calcium are specifically noted as a risk.


Q: Does Indrop-d start working immediately after the first dose?

According to the official product information, there is a time lag of 10 to 24 hours between the administration of the drug and the initiation of its effects. This time lag is related to the required metabolic steps the compound must undergo in the body to become fully active.


Q: Is it normal to feel tired after starting Indrop-d?

A general lack of strength or energy (asthenia) is documented as a less common adverse event in official summaries. Additionally, feeling weakness is also listed as an early sign of an overdose (Hypervitaminosis D).


Q: Does Indrop-d affect my ability to drive or operate machinery?

Official safety documents for medications listing CNS effects like dizziness or confusion may include a general warning. Patients experiencing these effects should exercise caution before driving or operating heavy machinery.


Q: Are there any risks associated with taking Indrop-d with alcohol?

Official regulatory data for interactions suggests no known specific interaction between Colecalciferol (Vitamin D3) and the consumption of alcohol. As with any medication, patients should discuss consumption with their healthcare provider.


Q: Is it true that Indrop-d has a black box warning?

A Black Box Warning (officially, a Boxed Warning) is a specific regulatory tool used to highlight the most serious safety risks on drug labels. Official sources for Colecalciferol products typically do not feature this particular type of warning.


Q: Are there any specific signs of an allergic reaction to Indrop-d?

Signs of a documented hypersensitivity reaction include skin symptoms such as urticaria (hives) and angioedema (swelling beneath the skin). These reactions are described in the drug's safety profile as possible, though rare.


Q: Can I take other drugs for the same condition while on Indrop-d?

Official warnings are specifically in place regarding the co-administration of Indrop-d with other high-dose Vitamin D or calcium products. This combination is documented to carry a risk of excessive blood calcium levels.

--UNS

Q: What are the specific conditions that Indrop-d is approved to treat?

Regulatory documents state that Indrop-d (Colecalciferol) is officially indicated for the treatment of conditions such as hypoparathyroidism, refractory rickets, and to address states of Vitamin D Deficiency or Insufficiency.

How should Indrop-d be stored and disposed of?

How to Store and Dispose of Indrop-d (Colecalciferol)

The official labeling for Indrop-d outlines specific storage and handling requirements. The medicine must be stored at room temperature, typically below 25 C (77 F), and must not be frozen.


Storage and Protection

Condition Requirement
Temperature Store below 25 C and away from excessive heat.
Protection Keep in the original container and protected from light.
Child Safety Must be kept out of the sight and reach of children.

Disposal Instructions

For oral solutions, any unused portion must be discarded after 60 days of first opening. Unused or expired Indrop-d should not be thrown away with wastewater or household trash. Dispose of the medicine in accordance with local requirements, often by consulting a pharmacist or utilizing community drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Indrop-d found in:

A-Z Index: